|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006826,
umls-concept:C0008838,
umls-concept:C0013089,
umls-concept:C0013216,
umls-concept:C0025677,
umls-concept:C0027651,
umls-concept:C0029246,
umls-concept:C0034656,
umls-concept:C0035168,
umls-concept:C0042670,
umls-concept:C0065452,
umls-concept:C0079459,
umls-concept:C0086418,
umls-concept:C0087111,
umls-concept:C0205179,
umls-concept:C0239307,
umls-concept:C0282461,
umls-concept:C0439658,
umls-concept:C0439858,
umls-concept:C0442711,
umls-concept:C1185740
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2001-5-15
|
|
pubmed:abstractText |
This randomized trial evaluated antitumor activity of and survival asociated with high-dose-intensity chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) plus granulocyte colony-stimulating factor (HD-MVAC) versus MVAC in patients with advanced transitional-cell carcinoma (TCC).
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:CollettiPP,
pubmed-author:European Organization for Research and Treatment of Cancer...,
pubmed-author:FossaS DSD,
pubmed-author:SchornagelJ HJH,
pubmed-author:SpinaMM,
pubmed-author:SternbergC NCN,
pubmed-author:ThéodoreCC,
pubmed-author:WitjesFF,
pubmed-author:de BalincourtCC,
pubmed-author:de MulderP HPH,
pubmed-author:van GroeningenC JCJ,
pubmed-author:van OosteromA TAT
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
19
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2638-46
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:11352955-Adult,
pubmed-meshheading:11352955-Aged,
pubmed-meshheading:11352955-Aged, 80 and over,
pubmed-meshheading:11352955-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11352955-Cisplatin,
pubmed-meshheading:11352955-Disease-Free Survival,
pubmed-meshheading:11352955-Doxorubicin,
pubmed-meshheading:11352955-Drug Administration Schedule,
pubmed-meshheading:11352955-Europe,
pubmed-meshheading:11352955-Female,
pubmed-meshheading:11352955-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:11352955-Humans,
pubmed-meshheading:11352955-Male,
pubmed-meshheading:11352955-Methotrexate,
pubmed-meshheading:11352955-Middle Aged,
pubmed-meshheading:11352955-Neoplasm Metastasis,
pubmed-meshheading:11352955-Recombinant Proteins,
pubmed-meshheading:11352955-Urinary Bladder Neoplasms,
pubmed-meshheading:11352955-Vinblastine
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924.
|
|
pubmed:affiliation |
Vincenzo Pansadoro Foundation, Rome, Italy. cstern@mclink.it
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial,
Multicenter Study,
Clinical Trial, Phase III
|
